Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

British Journal of Cancer

Volumn 102, Issue 5, 2010, Pages 799-802

  Newcomb, P A ^a,b   Trentham Dietz, A ^a   Hampton, J M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bisphosphonates; Breast cancer; Case control; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; OBESITY; OSTEOPOROSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OSTEOPOROSIS, POSTMENOPAUSAL; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; WISCONSIN; YOUNG ADULT;

EID: 77649269901     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605555     Document Type: Article

References (28)

1. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thurlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420-432
2. Bedard PL, Body JJ, Piccart-Gebhart MJ (2009) Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. J Clin Oncol 27: 4043-4046
3. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493
4. Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR (2004) A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol 159: 308-317
5. Boudreau DM, Doescher MP, Saver BG, Jackson JE, Fishman PA (2005) Reliability of Group Health Cooperative automated pharmacy data by drug benefit status. Pharmacoepidemiol Drug Saf 14: 877-884
6. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, Budillon A, Venuta S, Abbruzzese A (2004) The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 23: 6900-6913
7. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A (2006) Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13: 7-26
8. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276: 1404-1408
9. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242
10. Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221
11. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Post-lberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691
12. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97: 840-847
13. Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6: 213-218
14. Hiraga T, Williams PJ, Mundy GR, Yoneda T (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61: 4418-4424
15. Lipworth L, Fryzek J, Fored C, Blot W, McLaughlin J (2001) Comparison of surrogate with self-respondents regarding medical history and prior medication use. Int J Epidemiol 30: 303-308
16. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589
17. Neville-Webbe HL, Holen I, Coleman RE (2002) The anti-tumour activity of bisphosphonates. Cancer Treat Rev 28: 305-319
18. Newcomb PA, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, Willett WC, Stampfer MJ (2001) Fracture history and risk of breast and endometrial cancer. Am J Epidemiol 153: 1071-1078
19. Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353: 595-603
20. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106
21. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA (1999) The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 14(Suppl 2): 53-65
22. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26: 5465-5476
23. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468
24. Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe Jr L (2004) Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc 52: 1543-1548
25. Sprague BL, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2008) Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol 168: 404-411
26. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2009) Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 18: 284-290
27. Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453-475
28. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061